RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 LEADLESS II
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 28 suppl 2
SP 7
OP 8
DO 10.1177/1559897715612464
UL http://mdc.sagepub.com/content/15/28_suppl_2/7.abstract
AB In the LEADLESS II trial, a leadless cardiac pacemaker was demonstrated to be safe and effective. At 6 months, the serious device-related adverse events occurred in 5.7% of patients, and the primary efficacy end point of acceptable pacing capture threshold and therapeutically acceptable sensing amplitude was achieved in 90% of patients.